Stock Market Reviews

Read and share opinions on NNVC (NanoViricides, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• NanoViricides: Fiscal Q1 Earnings Snapshot
  Nov 14, 2025
• NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
  Nov 14, 2025
• NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
  Nov 12, 2025
• NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
  Nov 11, 2025
• NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
  Nov 10, 2025
• NNVC: Getting Set for Phase 2 Trial of NV-387 in MPox…
  Nov 6, 2025
• NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
  Nov 5, 2025
• NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
  Nov 3, 2025
• Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
  Oct 29, 2025
• NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
  Oct 27, 2025
• In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
  Oct 22, 2025
• A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
  Oct 20, 2025
• NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
  Oct 15, 2025
• NanoViricides, Inc. Has Filed its Annual Report
  Sep 30, 2025
• RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
  Sep 11, 2025
• NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
  Sep 9, 2025
• CEO Chat with Anil Diwan, President & Executive Chairman at NanoViricides, Inc.
  Sep 8, 2025
• A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
  Aug 18, 2025
• Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
  Jul 30, 2025
• NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
  Jul 23, 2025